Description
What Is NAD+ Nasal Spray?
NAD+ nasal spray is an intranasal delivery formulation of nicotinamide adenine dinucleotide (NAD+), the oxidized form of the essential coenzyme found in every living cell. NAD+ (CAS 53-84-9) carries the molecular formula C21H27N7O14P2⁺ with a molar mass of 664.4 g/mol. By delivering NAD+ directly across the nasal mucosa, this formulation bypasses the gastrointestinal tract and first-pass hepatic metabolism — the two primary barriers that limit oral NAD+ bioavailability in preclinical models.
NAD+ was first identified in 1906 by Arthur Harden and William John Young while studying yeast fermentation. Its role as a central redox coenzyme and substrate for longevity-associated enzymes — including sirtuins (SIRT1–SIRT7) and poly(ADP-ribose) polymerases (PARPs) — has made it one of the most studied molecules in cellular aging and metabolism research. PrymaLab NAD+ Nasal Spray is produced under strict quality control protocols, verified by independent HPLC and mass spectrometry analysis, and supplied exclusively for qualified research applications.
Mechanism of Action: How NAD+ Functions at the Cellular Level
NAD+ operates through four interconnected biochemical pathways that collectively regulate cellular energy status, genomic stability, stress response, and longevity signaling. Each of these pathways represents an active area of preclinical and clinical research.
Redox Coenzyme Function
NAD+ serves as the primary electron carrier in cellular metabolism, accepting hydride ions (H⁻) from substrates during glycolysis, beta-oxidation, and the citric acid cycle to become NADH. NADH then donates these electrons to the mitochondrial electron transport chain, driving ATP synthesis through oxidative phosphorylation. The NAD+/NADH ratio — typically approximately 700:1 in the cytoplasm of healthy mammalian cells — is a key indicator of cellular redox state and metabolic health. When this ratio declines, as observed during aging and metabolic stress, mitochondrial efficiency is impaired.
Sirtuin Activation
Sirtuins (SIRT1–SIRT7) are NAD+-dependent deacetylases that regulate gene expression, mitochondrial biogenesis, DNA repair, and inflammatory signaling by removing acetyl groups from histone and non-histone proteins. Because sirtuin activity is directly dependent on NAD+ availability, declining cellular NAD+ levels with age result in reduced sirtuin activity — a mechanism proposed to contribute to the hallmarks of cellular aging. Preclinical research demonstrates that restoring NAD+ levels rescues sirtuin activity in aged tissue models.
PARP Enzyme Substrate
Poly(ADP-ribose) polymerases (PARPs) consume NAD+ as a substrate during DNA damage repair, using it to synthesize poly(ADP-ribose) chains that recruit DNA repair machinery to sites of strand breaks. As genotoxic stress accumulates with aging, PARP activity increases and NAD+ is consumed at a faster rate. Li et al. (2017) demonstrated that declining NAD+ levels permit increased binding of DBC1 to PARP1, impairing DNA repair — a mechanism that may underlie age-related genomic instability.
CD38 and NAD+ Decline
CD38 is an ectoenzyme whose activity increases significantly with age and chronic inflammation, consuming NAD+ at rates that outpace biosynthetic capacity. Research by Camacho-Pereira et al. (2016, Cell Metabolism) demonstrated that CD38 knockout mice maintain higher NAD+ levels than wild-type controls throughout aging, and are protected from age-related metabolic decline. This pathway represents one of the most significant targets in age-related NAD+ depletion research.
NAD+ Nasal Spray Benefits: What Preclinical Research Shows
The following research context is drawn from peer-reviewed preclinical and translational literature. All data reflects research settings. PrymaLab NAD+ Nasal Spray is supplied exclusively for laboratory research and is not intended for human therapeutic use.
Cellular Energy Metabolism
NAD+ supplementation in aged animal models has been associated with restoration of mitochondrial NAD+ pools, improvement in the NAD+/NADH ratio, and enhanced ATP production efficiency. Studies using NMN and NR as oral NAD+ precursors have documented metabolic improvements in aged rodents; intranasal delivery of NAD+ itself offers a direct replenishment mechanism that bypasses the enzymatic conversion steps required by precursors, potentially providing faster intracellular availability in research models.
Neuroprotection and Cognitive Function
NAD+ plays a critical role in neuronal energy metabolism and DNA repair. Preclinical models of neurodegeneration — including Alzheimer’s and Parkinson’s disease paradigms — have been studied for NAD+ restoration effects. The intranasal delivery route is of particular research interest because it provides direct access to the central nervous system via olfactory transport pathways, potentially delivering NAD+ to brain tissue without requiring systemic distribution. Multiple published studies have examined the relationship between NAD+ levels, SIRT1 activity, and neuroinflammatory signaling in rodent brain models.
DNA Repair Capacity
PARP-mediated DNA repair is directly dependent on NAD+ availability. Research in aged cell models demonstrates that restoring NAD+ levels enhances DNA repair response to genotoxic insults, reduces the accumulation of unrepaired strand breaks, and modulates the DBC1–PARP1 interaction described by Li et al. (2017). These findings have driven significant research interest in NAD+ restoration as a strategy for maintaining genomic integrity in aging tissue models.
Sirtuin-Mediated Longevity Signaling
Animal studies examining NAD+ supplementation effects on sirtuin-dependent pathways have documented improvements in mitochondrial biogenesis (via SIRT1/PGC-1α axis), reduced oxidative stress markers, enhanced autophagy signaling, and improvements in metabolic parameters in aged mice. Shin-ichiro Imai’s “NAD World” hypothesis (2009, expanded 2016) proposes that maintaining NAD+ levels in the hypothalamus via NAMPT activity is a central regulatory mechanism for systemic aging.
Inflammatory Modulation
NAD+ depletion activates inflammatory pathways in part through impaired SIRT1 deacetylation of NF-κB subunits. Preclinical research suggests that restoring NAD+ availability attenuates NF-κB-driven inflammatory gene expression in aged tissue models, potentially through both sirtuin-dependent and CD38-related mechanisms. This area is an active focus of translational aging research.
NAD+ Nasal Spray vs Injection: Delivery Route Comparison
Researchers evaluating NAD+ supplementation must consider how delivery route affects bioavailability, onset kinetics, CNS access, and practical experimental design. The comparison below reflects published pharmacokinetic and preclinical data.
| Feature | NAD+ Nasal Spray | NAD+ Injection (IV/SC) | Oral NAD+ / Precursors |
|---|---|---|---|
| Route | Intranasal | Intravenous / Subcutaneous | Oral / Sublingual |
| First-pass metabolism | Bypassed | Bypassed | Significant hepatic first-pass |
| GI degradation | Avoided | Avoided | Substantial in acidic environment |
| CNS access route | Direct — olfactory/trigeminal nerve transport | Indirect — crosses BBB via systemic circulation | Indirect — requires precursor conversion |
| Administration complexity | Low — non-invasive | High — requires sterile technique, injection | Low |
| Onset of systemic distribution | Rapid (minutes) | Rapid (IV: seconds; SC: 15–30 min) | Slow (requires conversion to NMN → NAD+) |
| Research use case | CNS-targeted studies, non-invasive dosing protocols | Precise systemic dosing, high-dose acute studies | Chronic supplementation, precursor comparison studies |
| Precursor conversion required | No — direct NAD+ delivery | No — direct NAD+ delivery | Yes — NMN or NR must be enzymatically converted |
The intranasal route is particularly valuable in research protocols targeting central nervous system endpoints, where direct olfactory transport provides access to brain parenchyma independent of blood-brain barrier permeability. For peripheral metabolic research, intravenous injection delivers NAD+ with the highest precision, while nasal spray offers a practical non-invasive alternative for chronic dosing studies in animal models.
NAD+ Nasal Spray Dosage: Research Concentrations and Protocols
The following dosage information is extracted from published preclinical research and existing clinical investigation protocols. It is provided strictly as research reference data. PrymaLab does not prescribe dosing for human use.
Available Concentrations
| Concentration | NAD+ per mL | Volume per Spray | NAD+ per Spray | Total per 10 mL Vial |
|---|---|---|---|---|
| 50 mg/mL | 50 mg | 0.1 mL | 5 mg | 500 mg |
| 100 mg/mL | 100 mg | 0.1 mL | 10 mg | 1,000 mg |
| 200 mg/mL | 200 mg | 0.1 mL | 20 mg | 2,000 mg |
Animal Model Reference Doses from Published Literature
| Research Application | Species | Dose Range | Route | Duration |
|---|---|---|---|---|
| Metabolic / aging models | Mouse | 300–500 mg/kg/day | Various | 7–90 days |
| Neuroprotection studies | Rat/Mouse | 50–100 mg/kg | Intranasal / IV | Acute to 14 days |
| DNA repair / genotoxic stress | Mouse | 400–500 mg/kg | IP / SC | Single to 7 days |
| Sirtuin activation studies | Mouse | 100–300 mg/kg | Various | 14–30 days |
Storage and Stability
NAD+ solutions are sensitive to pH and temperature. PrymaLab NAD+ Nasal Spray is formulated in a buffered solution at neutral pH to maximize stability. Store refrigerated at 2–8°C, protected from light. Solution stability is approximately 7–14 days under proper refrigerated storage. For longer storage, lyophilized (freeze-dried) NAD+ powder is stable at −20°C for 12–24 months when stored desiccated. Do not expose to acidic or alkaline conditions, which cause rapid degradation. Each vial is supplied with storage instructions and stability data in the accompanying certificate of analysis.
NAD+ Precursors vs Direct NAD+ Nasal Spray
A common research question concerns whether intranasal NAD+ delivers meaningfully different results compared to oral precursors such as NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside). The distinction matters because precursors must undergo enzymatic conversion — via NAMPT and NMN adenylyltransferase — before yielding intracellular NAD+, while direct NAD+ delivery bypasses these steps.
| Factor | Direct NAD+ (Nasal Spray) | NMN (Oral/Injection) | NR (Oral) |
|---|---|---|---|
| Conversion steps to NAD+ | 0 — direct delivery | 1 — NMN adenylyltransferase | 2 — NR kinase → NMNAT |
| Rate-limiting enzyme dependency | None | NMNAT activity | NRK1 + NMNAT activity |
| CNS penetration | Direct via olfactory route | Systemic — BBB-dependent | Systemic — BBB-dependent |
| Stability | pH-sensitive — requires buffered formulation | More stable — tolerates wider pH range | Stable — well-tolerated oral form |
| Research use advantage | Direct CNS studies; bypass of enzymatic variability | Well-documented chronic supplementation data | Extensive human trial data; oral bioavailability |
PrymaLab Quality Assurance
Every batch of PrymaLab NAD+ Nasal Spray is subject to a multi-stage quality assurance protocol before release. Our quality framework is designed to meet the rigorous standards required for credible preclinical research.
- HPLC Purity Analysis: Each batch is tested by high-performance liquid chromatography to confirm NAD+ purity of ≥98%. The chromatography report is included in the certificate of analysis provided with every order.
- Mass Spectrometry Identity Confirmation: ESI-MS or MALDI-TOF mass spectrometry confirms the molecular identity of NAD+ (MW 664.4 g/mol, formula C21H27N7O14P2⁺) in every batch, ruling out degradation products or substitutions.
- pH and Formulation Verification: Solution pH is verified to confirm the neutral range required for NAD+ stability. Our buffered formulation extends solution shelf life beyond unbuffered alternatives.
- Sterility and Endotoxin Testing: All solution formulations are tested for microbial sterility and bacterial endotoxin levels, ensuring suitability for in vivo animal research protocols.
- Third-Party Independent Testing: Quality verification is conducted by an independent accredited laboratory, separate from our production facility, to ensure objective and unbiased results.
- Lot Traceability: Every vial carries a unique lot number that traces back to raw material sourcing, synthesis batch, pH testing, and HPLC/MS analytical records — supporting GLP-aligned research documentation requirements.
Frequently Asked Questions About NAD+ Nasal Spray
What is NAD+ nasal spray and how does it work?
NAD+ nasal spray is an intranasal formulation of nicotinamide adenine dinucleotide (CAS 53-84-9), a coenzyme essential to cellular energy metabolism, DNA repair, and sirtuin signaling. By delivering NAD+ across the nasal mucosa directly into systemic circulation and — via olfactory nerve transport — into the central nervous system, intranasal delivery bypasses the gastrointestinal degradation and first-pass hepatic metabolism that limit oral NAD+ bioavailability in preclinical models.
Does NAD+ nasal spray work better than oral NAD+ supplements?
In preclinical research models, intranasal NAD+ delivery offers two key advantages over oral supplementation: it bypasses GI degradation (NAD+ is sensitive to acidic conditions in the stomach) and it provides direct access to the CNS via olfactory nerve transport routes, independent of blood-brain barrier permeability. Direct NAD+ also requires zero enzymatic conversion steps, unlike precursors NMN and NR which must be enzymatically converted before yielding intracellular NAD+.
What is the difference between NAD+ nasal spray and injection?
Both intranasal and intravenous NAD+ delivery bypass GI metabolism and hepatic first-pass. The key distinction is CNS access: intranasal delivery leverages olfactory and trigeminal nerve transport to deliver NAD+ directly to brain tissue, making it particularly valuable for neuroprotection and cognitive research protocols. Intravenous injection provides the most precise systemic dosing control for peripheral metabolic studies. Nasal spray offers a practical non-invasive alternative suitable for chronic dosing designs in animal models.
What concentration of NAD+ nasal spray should be used for research?
PrymaLab offers NAD+ Nasal Spray in 50 mg/mL, 100 mg/mL, and 200 mg/mL concentrations. Published preclinical research on NAD+ restoration in rodent aging models has used doses ranging from 50–500 mg/kg depending on the endpoint studied. The appropriate concentration depends on the specific animal model, endpoint, and administration frequency. Researchers should calculate doses from published literature appropriate to their specific protocol and species.
What are the side effects of NAD+ nasal spray in research models?
In preclinical animal studies, NAD+ administration is generally well-tolerated across a wide dose range. The most commonly noted observations include transient nasal mucosal irritation at the instillation site with repeated intranasal dosing, and mild flushing responses at high systemic doses in some rodent models — consistent with niacin-related vasodilatory effects. No serious toxicity, organ damage, or mortality has been documented at standard research doses in published animal studies. Long-term safety data in humans from well-controlled trials remains limited.
How should NAD+ nasal spray be stored?
NAD+ solution formulations should be stored at 2–8°C (refrigerated), protected from light, and maintained at neutral pH. Under these conditions, solution stability is approximately 7–14 days. NAD+ is rapidly degraded by acidic or alkaline conditions, heat, and light. For long-term storage, lyophilized NAD+ powder is stable at −20°C for up to 24 months when stored desiccated. All PrymaLab products include storage instructions on the label and in the certificate of analysis.
Is NAD+ nasal spray a prescription product?
NAD+ is not a scheduled or controlled substance in the United States. Compounded NAD+ formulations have been used in clinical infusion settings by licensed practitioners, but NAD+ nasal spray as supplied by PrymaLab is intended exclusively for laboratory research purposes — not for human therapeutic use or clinical administration. Researchers outside the US should verify regulatory status in their jurisdiction. PrymaLab sells NAD+ Nasal Spray solely to qualified buyers who confirm intended research use.
Research Disclaimer
All PrymaLab products, including NAD+ Nasal Spray, are intended exclusively for in vitro laboratory research and in vivo animal studies conducted by qualified researchers in appropriate institutional settings. These products are not approved by the FDA or any equivalent regulatory authority for human therapeutic use. They are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Not for human consumption. Not for sale to minors. Researchers are solely responsible for compliance with all applicable federal, state, and local regulations governing the acquisition, storage, and use of research compounds. NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring coenzyme; this product supplies purified NAD+ in a research-grade intranasal formulation.
Reviews
There are no reviews yet.